These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 29709421)
1. Correlates of immune and clinical activity of novel cancer vaccines. van der Burg SH Semin Immunol; 2018 Oct; 39():119-136. PubMed ID: 29709421 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic vaccination with tumor cells that engage CD137. Hellstrom KE; Hellstrom I J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523 [TBL] [Abstract][Full Text] [Related]
3. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. Lam H; McNeil LK; Starobinets H; DeVault VL; Cohen RB; Twardowski P; Johnson ML; Gillison ML; Stein MN; Vaishampayan UN; DeCillis AP; Foti JJ; Vemulapalli V; Tjon E; Ferber K; DeOliveira DB; Broom W; Agnihotri P; Jaffee EM; Wong KK; Drake CG; Carroll PM; Davis TA; Flechtner JB Cancer Discov; 2021 Mar; 11(3):696-713. PubMed ID: 33504579 [TBL] [Abstract][Full Text] [Related]
4. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide. Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225 [TBL] [Abstract][Full Text] [Related]
5. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model. Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884 [TBL] [Abstract][Full Text] [Related]
6. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391 [TBL] [Abstract][Full Text] [Related]
7. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells. Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434 [TBL] [Abstract][Full Text] [Related]
8. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors. Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015 [TBL] [Abstract][Full Text] [Related]
9. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
10. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. Johnson LE; Olson BM; McNeel DG J Immunother Cancer; 2017 Jul; 5(1):56. PubMed ID: 28716080 [TBL] [Abstract][Full Text] [Related]
11. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754 [TBL] [Abstract][Full Text] [Related]
12. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Bodey B; Bodey B; Siegel SE; Kaiser HE Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341 [TBL] [Abstract][Full Text] [Related]
13. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. Pavlenko M; Leder C; Pisa P Expert Rev Vaccines; 2005 Jun; 4(3):315-27. PubMed ID: 16026247 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Marshall DJ; Rudnick KA; McCarthy SG; Mateo LR; Harris MC; McCauley C; Snyder LA Vaccine; 2006 Jan; 24(3):244-53. PubMed ID: 16135392 [TBL] [Abstract][Full Text] [Related]
15. Next generation approaches for tumor vaccination. Patel A; Kaufman HL; Disis ML Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672 [TBL] [Abstract][Full Text] [Related]
16. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses. Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689 [TBL] [Abstract][Full Text] [Related]
18. Tumor resistance to CD8+ T cell-based therapeutic vaccination. Huang Y; Shah S; Qiao L Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376 [TBL] [Abstract][Full Text] [Related]
19. Emerging strategies in tumor vaccines. Le Poole IC; Gerberi MA; Kast WM Curr Opin Oncol; 2002 Nov; 14(6):641-8. PubMed ID: 12409655 [TBL] [Abstract][Full Text] [Related]
20. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity. Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]